Article Details
Retrieved on: 2024-10-14 14:46:23
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Spyre Therapeutics (NASDAQ: SYRE) announced accelerated timelines for SPY003, its novel half-life extended IL-23p19 monoclonal antibody, ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here